NCT01132911已完成1 期
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- To determine the maximum tolerated dose and Phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.
研究概览
简要总结
Background:
- Vorinostat and bortezomib are anti-tumor drugs that have been approved by the Food and Drug Administration to treat different kinds of myeloma and lymphoma in adults. The combination of these two drugs has been tried in a small number of adults, but it has not been formally approved and is experimental, particularly in children. Researchers are interested in determining safe and effective treatment doses of vorinostat and bortezomib in children, and learning more about how these drugs affect tumor growth and human development.
Objectives:
- To determine safe and effective doses of vorinostat and bortezomib to treat solid tumors in children.
- To study the effects of vorinostat and bortezomib on blood cells, blood flow, and human development.
Eligibility:
- Children, adolescents, and young adults between 1 and 21 years of age who have been diagnosed with solid tumors that have not responded to treatment.
Design:
- Eligible participants will be screened with a physical examination, blood and tumor samples, and imaging studies.
- Participants will have 21-day treatment cycles of vorinostat and bortezomib. Vorinostat will be given as either tablets or liquid doses on days 1 through 5 and 8 through 12 of each cycle. Bortezomib will be given as an intravenous injection on days 1, 4, 8, and 11 of each cycle. Participants will keep a drug administration diary to record information about side effects or other problems with the treatment.
- Participants may continue to receive vorinostat and bortezomib for up to 2 years unless serious side effects develop or the tumor does not respond to treatment.
- Additional blood samples will be taken at regular intervals for the first 3 days after the first bortezomib dose and for the first 2 days after the first vorinostat dose of the first treatment cycle.
详细描述
Background:
-The combination of vorinostat and bortezomib has been shown to be synergistic in vitro in a variety of malignancies, including hepatoma, multiple myeloma, leukemia, lymphoma, and gastrointestinal cancer. Currently several phase 2 adult studies are underway evaluating combination therapy.
Objectives:
- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of the combination of oral vorinostat administered on days 1-5 and 8-12 and bortezomib administered intravenously on days 1, 4, 8, 11, every 21 days to children with refractory or recurrent solid tumors.
- To define and describe the toxicities of vorinostat in combination with bortezomib administered on this schedule.
- To characterize the pharmacokinetics of vorinostat and bortezomib in combination in children with refractory or recurrent solid tumors.
- Secondary objectives include preliminary definition of the antitumor activity of these agents when administered together; and assessment of the biologic activity of bortezomib by measuring NF-kappaB activity in peripheral blood mononuclear cells (PBMC) and by measuring endoplasmic reticulum stress response using the GRP78 molecular chaperone marker in PBMC.
Eligibility:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than12 months and less than or equal to 21 years of age with a diagnosis and histologic verification (except patients with instrinsic brain stem tumors, optic pathway gliomas or pineal tumors) of measureable or evaluable relapsed or refractory solid tumors including CNS tumors and lymphomas are eligible.
- •Current disease state must be one for which there is no known curative therapy, or therapy proven to prolong survival.
- •Performance score: Karnofsky greater than or equal to 60% for patients greater than 16 years of age; Lansky greater than or equal to 60 for patients less than or equal to 16 years of age.
- •Must have fully recovered from acute toxic effects from all prior therapy which have been completed within the specified prior time frame.
- •Have adequate organ function as determined by laboratory evaluation.
排除标准
- 未提供
结局指标
主要结局
To determine the maximum tolerated dose and Phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.
Define toxicities and pharmacokinetics.
次要结局
- To define antitumor activity, assess biological activity of bortezomib by measuring NF-kb activity in PBMC and to assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress response using GRP78 molecular chaperone marke...
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaChildhood Burkitt LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood MedulloepitheliomaChildhood MeningiomaChildhood Mixed GliomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChildhood OligodendrogliomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00994500National Cancer Institute (NCI)20
终止
2 期
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesMixed Lineage Acute LeukemiaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaNCT02419755St. Jude Children's Research Hospital12
撤回
2 期
Relapsed and/or Refractory Non-Hodgkin Lymphoma StudyNon-Hodgkin LymphomaNCT00837174The Methodist Hospital Research Institute
终止
1 期
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00744354UNC Lineberger Comprehensive Cancer Center32
已完成
2 期
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00641706National Cancer Institute (NCI)44